The $654,000,000 decline in fourth quarter NAV was primarily driven by share price weakness in CVI, which overshadowed an 11% gain in the investment funds.

Management attributes the CVI decline to temporary market sentiment rather than fundamental changes, citing limited global capacity and new pipeline projects as medium-term profitability drivers.

The investment fund's performance was bolstered by EchoStar's spectrum valuation, Sentry's infrastructure growth, and refining hedges, while Caesars served as the primary detractor due to stock underperformance.

Strategic positioning has shifted toward a more cautious market view, prioritizing defensive assets like AEP that are positioned to benefit from AI infrastructure buildout.

The exit from Southwest Gas followed a successful collaboration that improved return on equity and strengthened the balance sheet through the Great Basin Pipeline Expansion.

Management is maintaining a significant 'war chest' with fund cash balances increasing to over $1.2 billion to capitalize on market dislocations.

CVI is focusing on improving capture rates to drive profitability even if industry crack spreads remain stagnant in the near term.

AEP is projected to grow its asset base at a 10% CAGR and EPS at a 9% CAGR through 2030, supported by a $72,000,000,000 capital expenditure plan.

Management views a potential SpaceX IPO as a meaningful catalyst for EchoStar due to the value of its spectrum portfolio and SpaceX equity holdings.

The Pharma segment expects to dose the first patient in its TRANSCEND trial for a PAH drug within the next 60 to 90 days, targeting a disease-modifying designation.

Home Fashion anticipates that tariff uncertainty may drive new business into the bidding pipeline, potentially impacting 2026 results positively.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Energy segment EBITDA was pressured by a turnaround at the Coffeyville fertilizer facility and a three-week downtime event at a third-party air separation plant.

Food Packaging underwent a leadership change, reinstating former CEO Tom Davis to navigate manufacturing inefficiencies and restructuring headwinds.

Pharma segment performance was negatively impacted by the entry of generic competition in the anti-obesity market.

The company took proactive steps to strengthen its capital structure by calling in the remaining balance of its 2026 corporate debt maturities.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.